Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Early Breast Cancer Specialty Channel

Early Breast Cancer
Specialty Channel
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
Quiz
Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer
08/05/2024
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to...
08/05/2024
Oncology
News
Addition of Everolimus to Endocrine Therapy Did Not Improve Survival, Increased Toxicity Among Patients With High-Risk HR-Positive Early-Stage Breast Cancer
07/17/2024
Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.
Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.
Results from the SWOG S127 study...
07/17/2024
Oncology
Quiz
Improving Long-Term Outcomes for Patients With HER2-Positive Early-Stage Invasive Breast Cancer
07/15/2024
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis...
07/15/2024
Oncology
News
Trastuzumab Emtansine Improved Long-Term Outcomes Among Patients With HER2-Positive Early Breast Cancer
07/08/2024
Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.
Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.
Long-term results from the phase...
07/08/2024
Oncology
Quiz
Carboplatin Plus Standard Chemotherapy for Patients With Early-Stage Triple-Negative Breast Cancer
06/28/2024
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in...
06/28/2024
Oncology
Pier Franco Conte, MD
Conference Coverage
Adjuvant Avelumab for High-Risk Patients with Early Triple-Negative Breast Cancer
06/19/2024
Pier Franco Conte, MD
Pier Franco Conte, MD, shares insights on the phase 3 A-BRAVE trial evaluating adjuvant avelumab for high-risk patients with early triple-negative breast cancer.
Pier Franco Conte, MD, shares insights on the phase 3 A-BRAVE trial evaluating adjuvant avelumab for high-risk patients with early triple-negative breast cancer.
Pier Franco Conte, MD, shares...
06/19/2024
Oncology
Conference Coverage
Addition of Carboplatin to Anthracycline and Taxane Therapy Improved Event-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer
06/17/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer.
According to results from the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer.
According to results from the...
06/17/2024
Oncology
News
Ribociclib Added to Endocrine Therapy Improved Disease-Free Survival Among Patients With HR-Positive, HER2-Negative Early Breast Cancer
04/04/2024

Stephanie Holland

Stephanie Holland
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results...
04/04/2024
Oncology
News
Fulvestrant Did Not Significantly Improve Response Rate Compared to Anastrozole in ER-Positive, HER2-Negative Early Breast Cancer
02/09/2024

Stephanie Holland 

Stephanie Holland 
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial...
02/09/2024
Oncology
News
Trastuzumab Emtansine Improved Survival Among Patients With Residual Invasive HER2-Positive Early Breast Cancer
12/08/2023
Allison Casey
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the...
12/08/2023
Oncology

The Latest News

News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Addition of Everolimus to Endocrine Therapy Did Not Improve Survival, Increased Toxicity Among Patients With High-Risk HR-Positive Early-Stage Breast Cancer
07/17/2024
Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.
Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.
Results from the SWOG S127 study...
07/17/2024
Oncology
News
Trastuzumab Emtansine Improved Long-Term Outcomes Among Patients With HER2-Positive Early Breast Cancer
07/08/2024
Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.
Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.
Long-term results from the phase...
07/08/2024
Oncology
Pier Franco Conte, MD
Conference Coverage
Adjuvant Avelumab for High-Risk Patients with Early Triple-Negative Breast Cancer
06/19/2024
Pier Franco Conte, MD
Pier Franco Conte, MD, shares insights on the phase 3 A-BRAVE trial evaluating adjuvant avelumab for high-risk patients with early triple-negative breast cancer.
Pier Franco Conte, MD, shares insights on the phase 3 A-BRAVE trial evaluating adjuvant avelumab for high-risk patients with early triple-negative breast cancer.
Pier Franco Conte, MD, shares...
06/19/2024
Oncology
Conference Coverage
Addition of Carboplatin to Anthracycline and Taxane Therapy Improved Event-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer
06/17/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer.
According to results from the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer.
According to results from the...
06/17/2024
Oncology
News
Ribociclib Added to Endocrine Therapy Improved Disease-Free Survival Among Patients With HR-Positive, HER2-Negative Early Breast Cancer
04/04/2024

Stephanie Holland

Stephanie Holland
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results...
04/04/2024
Oncology
News
Fulvestrant Did Not Significantly Improve Response Rate Compared to Anastrozole in ER-Positive, HER2-Negative Early Breast Cancer
02/09/2024

Stephanie Holland 

Stephanie Holland 
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial...
02/09/2024
Oncology
News
Trastuzumab Emtansine Improved Survival Among Patients With Residual Invasive HER2-Positive Early Breast Cancer
12/08/2023
Allison Casey
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the...
12/08/2023
Oncology
News
Omission of Sentinel Lymph Node Biopsy Safe For Patients With Early Breast Cancer With Negative Ultrasonography of Axillary Lymph Nodes
11/29/2023

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 SOUND study, omitting sentinel lymph node biopsy is safe for patients with early breast cancer who have negative results on ultrasonography of the axillary lymph node when the lack of pathological...
According to results from the phase 3 SOUND study, omitting sentinel lymph node biopsy is safe for patients with early breast cancer who have negative results on ultrasonography of the axillary lymph node when the lack of pathological...
According to results from the...
11/29/2023
Oncology
Conference Coverage
NATALEE Trial Results Support Ribociclib Plus Endocrine Therapy for HR-Positive, HER2-Negative Early Breast Cancer
06/05/2023

Janelle Bradley

Janelle Bradley
Ribociclib added to endocrine therapy improves invasive disease-free survival in patients with HR-positive, HER2-negative early breast cancer according to findings from the NATALEE trial presented at the ASCO Annual Meeting.
Ribociclib added to endocrine therapy improves invasive disease-free survival in patients with HR-positive, HER2-negative early breast cancer according to findings from the NATALEE trial presented at the ASCO Annual Meeting.
Ribociclib added to endocrine...
06/05/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
Nirav Shah, MD
Videos
Innovation and the Future Development of Cell Therapies for Patients With B-Cell Lymphomas
08/05/2024
At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.
At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.
At the 2024 Pan Pacific Lymphoma...
08/05/2024
Oncology
Curtis Lachowiez, MD
Videos
Exploring Triplet Therapy for Patients With AML Ineligible for Intensive Induction Chemotherapy
08/05/2024
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD,...
08/05/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
Rene Adam, MD, PhD
Conference Coverage
Chemotherapy and Liver Transplantation for Patients With Unresectable Colorectal Liver Metastases
08/02/2024
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses...
08/02/2024
Oncology

Quizzes

Quiz
Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer
08/05/2024
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to...
08/05/2024
Oncology
Quiz
Improving Long-Term Outcomes for Patients With HER2-Positive Early-Stage Invasive Breast Cancer
07/15/2024
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis...
07/15/2024
Oncology
Quiz
Carboplatin Plus Standard Chemotherapy for Patients With Early-Stage Triple-Negative Breast Cancer
06/28/2024
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in...
06/28/2024
Oncology
Quiz
Ribociclib Plus a Nonsteroidal Aromatase Inhibitor for HR-Positive, HER2-Negative Early Breast Cancer
11/08/2023
Which of the following statements about the results of the NATALEE study are true.
Which of the following statements about the results of the NATALEE study are true.
Which of the following...
11/08/2023
Oncology
Quiz
Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer
08/08/2024
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance...
08/08/2024
Oncology
Quiz
Recommended Dostarlimab Dose for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/08/2024
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase...
08/08/2024
Oncology
Quiz
Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer
08/05/2024
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to...
08/05/2024
Oncology
Quiz
Improving Long-Term Outcomes for Patients With HER2-Positive Early-Stage Invasive Breast Cancer
07/15/2024
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis...
07/15/2024
Oncology
Quiz
Ibrutinib Plus Venetoclax For Patients With TP53-Mutated Mantle Cell Lymphoma
07/12/2024
07/12/2024
Oncology
Quiz
Weekly Combination Therapy for Patients With R/R Multiple Myeloma
07/11/2024
07/11/2024
Oncology
Quiz
Examining the Efficacy of Azacitidine Plus Ruxolitinib in Myelofibrosis Treatment
07/03/2024
07/03/2024
Oncology
Quiz
FDA Approval of Lisocabtagene Maraleucel for MCL
07/01/2024
07/01/2024
Oncology
Quiz
Carboplatin Plus Standard Chemotherapy for Patients With Early-Stage Triple-Negative Breast Cancer
06/28/2024
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in...
06/28/2024
Oncology
Quiz
Treatment Options for a Patient With Early-Stage Non-Small Cell Lung Cancer
06/26/2024
What adjuvant treatment would you recommend?
What adjuvant treatment would you recommend?
What adjuvant treatment would...
06/26/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Addition of Everolimus to Endocrine Therapy Did Not Improve Survival, Increased Toxicity Among Patients With High-Risk HR-Positive Early-Stage Breast Cancer
07/17/2024
Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.
Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.
Results from the SWOG S127 study...
07/17/2024
Oncology
News
Trastuzumab Emtansine Improved Long-Term Outcomes Among Patients With HER2-Positive Early Breast Cancer
07/08/2024
Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.
Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.
Long-term results from the phase...
07/08/2024
Oncology
Conference Coverage
Addition of Carboplatin to Anthracycline and Taxane Therapy Improved Event-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer
06/17/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer.
According to results from the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer.
According to results from the...
06/17/2024
Oncology
News
Ribociclib Added to Endocrine Therapy Improved Disease-Free Survival Among Patients With HR-Positive, HER2-Negative Early Breast Cancer
04/04/2024

Stephanie Holland

Stephanie Holland
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results...
04/04/2024
Oncology
News
Fulvestrant Did Not Significantly Improve Response Rate Compared to Anastrozole in ER-Positive, HER2-Negative Early Breast Cancer
02/09/2024

Stephanie Holland 

Stephanie Holland 
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial...
02/09/2024
Oncology
News
Trastuzumab Emtansine Improved Survival Among Patients With Residual Invasive HER2-Positive Early Breast Cancer
12/08/2023
Allison Casey
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the...
12/08/2023
Oncology
News
Omission of Sentinel Lymph Node Biopsy Safe For Patients With Early Breast Cancer With Negative Ultrasonography of Axillary Lymph Nodes
11/29/2023

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 SOUND study, omitting sentinel lymph node biopsy is safe for patients with early breast cancer who have negative results on ultrasonography of the axillary lymph node when the lack of pathological...
According to results from the phase 3 SOUND study, omitting sentinel lymph node biopsy is safe for patients with early breast cancer who have negative results on ultrasonography of the axillary lymph node when the lack of pathological...
According to results from the...
11/29/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement